Cipla share news, announcements and annual reports
NSE: CIPLABSE: 500087Pharmaceuticals & BiotechnologyLarge Cap
Cipla Limited · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jul 1983 on BSE, Feb 1995 on NSE
Last close ₹1,387.00up ₹8.10 (0.59%)BSE ₹1,382.00
Share price at the NSE close on 2 Nov 2026. Previous close ₹1,378.90.
2 Nov: open ₹1,383.00, high ₹1,391.00, low ₹1,364.60
52-week range of traded prices to 2 Nov 2026
₹1,165.70Low, 2 Apr 2026₹1,539.70High, 6 Jan 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹1,12,052 Cr99th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 38.68
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 3.17
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.94%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 8.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 9.7%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.01
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 13,77,33662.2% delivered
Cipla share news and announcements
1,563 announcements, routine notices left out, newest first. Page 26 of 32.
Apr 2015
Mar 2015
Feb 2015
13 Feb · Legal
Exchange has sought clarification from Cipla Limited with respect to recent news item captioned "Cipla to Launch generic of Gilead's Hepatitis C Drug". In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company are aware of any information that has not been announced to the Exchanges under clause 36 of the Listing Agreement. The response from the Company is awaited.4 Feb · Board meeting
Inter alia, to consider and approve unaudited financial results for the quarter and nine months ended December 31, 2014.
Jan 2015
12 Jan · Disclosure of Voting Pattern - Clause 35A
12 Jan · Meeting
Dec 2014
17 Dec · Legal
Exchange has sought clarification from Cipla Limited with respect to recent news item captioned "Novartis drags Cipla to court". In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company are aware of any information that has not been announced to the Exchanges under clause 36 of the Listing Agreement. The response from the Company is awaited.
Nov 2014
13 Nov · Board meeting
5 Nov · Board meeting
Inter alia to consider and approve unaudited financial results for the quarter and half year ended September 30, 2014.
Oct 2014
10 Oct · Rating
India Ratings & Research Private Limited, a Fitch Group Company have affirmed the Long-Term Issuer Rating of 'IND AAA' to the Company and 'IND A1+' rating to the Company's Rs.10 billion Commercial Paper/Short Term Debt Programme. Further, India Ratings & Research Private Limited has assigned 'IND AAA' rating to the Company's proposed Rs. 20 billion NCD programme.
Sep 2014
5 Sep · Updates
Medispray Laboratories Private Limited, a wholly owned subsidiary of the Company at its board meeting held on September 05, 2014 approved the acquisition of two manufacturing undertakings. A significant portion of the capacities of the two undertaking are dedicated for the manufacture of Cipla's product. Acquisition of the aforesaid undertaking is expected to yield operational synergies. The consideration for the above two transactions are Rs. 29 crore and Rs. 71.93 crore respectively. The first manufacturing facility located at Goa is owned by Okasa Private Limited and second manufacturing facility located at Satara ( Maharashtra ) is owned by Okasa Pharma Pvt. Ltd. Entities controlled by relatives of the promoters hold majority interest in the companies which own the aforesaid undertakings. The consideration for these transactions were supported on the basis of valuation reports from Price Waterhouse & Co. LLP and fairness opinions provided by Kotak Mahindra Capital Company Limited.5 Sep · Disclosure of Voting Pattern - Clause 35A
4 Sep · Management
Mr. Pankaj Patel, Director has resigned from the directorship of the Company due to his increasing professional commitments.
Aug 2014